12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cabozantinib: Additional Phase III data

Additional data from the double-blind, international Phase III EXAM trial in 330 patients with locally advanced or metastatic MTC showed that once-daily cabozantinib led to a 1-year PFS rate of 47.3% vs. 7.2% for placebo. Median duration of response was 14.6 months. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Exelixis previously reported that cabozantinib met the primary...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >